Press release from Companies

Published: 2020-01-06 21:38:30

WntResearch AB: WntResearch announces the passing of board member Sten Trolle after a short illness

It is with deep sadness that WntResearch is forced to announce that the member of the board Sten Trolle has passed away after a short illness. He was one of the founders of WntResearch, and participated actively in the operations during the first years. Sten Trolle was reelected to the board of WntResearch in 2018. With his long and solid experience, Sten Trolle provided the board with a valuable contribution of knowledge and strong commitment.

"It is a man of honor who has passed away, and Sten"s extensive experience and wise remarks will be dearly missed by the board. We extend our sincere condolences, and our thoughts are with Sten"s family," says Gudrun Anstrén, Chairman of WntResearch.

For more information, please contact:

Peter Morsing, CEO, WntResearch AB
E-mail: pm@wntresearch.coman

Telephone: +46 727 200711

This information is information that WntResearch AB is obliged to make public

pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency

of the contact person set out above, on January 6, 2020.

About WntResearch

WntResearch is developing an entirely new kind of cancer drug, which inhibits the tumour cells" ability to spread through the body and metastasize. The majority of cancer deaths are due to metastases, and there are no therapies available that can prevent that. Foxy-5, the Company"s most advanced drug candidate, is a peptide that mimics the body"s own WNT5A protein. In preclinical trials, Foxy-5 has demonstrated ability to suppress the mobility and invasive power of cancer cells, and thus to inhibit metastasis. Phase 1 studies on patients with colon, prostate and breast cancer have demonstrated a good safety profile and favourable pharmacokinetics, and early data indicates biological activity. A Phase 2 multicenter study is underway on patients with colon cancer, in order to study the anti-metastasizing efficacy of Foxy-5. WntResearch"s share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com

Läs mer hos Cision
Read more about WntResearch AB

Subscription